Somayaji, R.
Goss, C. H.
Article History
First Online: 26 November 2019
Compliance with Ethical Standards
:
: Ranjani Somayaji declares no conflict of interest. Christopher Goss reports grants from Cystic Fibrosis Foundation, grants from European Commission, grants from NIH (NHLBI), grants from NIH (NIDDK and NCRR), personal fees from Gilead Sciences for serving as a Chair of a Grant Review Committee; personal fees from Novartis serving as a DSMB Chair for a trial supported by Novartis and the European Commission, grants from NIH, and grants from FDA for funding to study a novel antimicrobial in cystic fibrosis, and served a US lead in a phase 2 trial of novel therapy for cystic fibrosis support from Boehringer Ingelheim.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: None of the work presented in this opinion piece was influenced by the funding sources noted above. The funding sources that support other ongoing researches played no role in writing this manuscript, or in the decision to submit for publication.